

(b) detecting binding of the antibody, or antibody fragment thereof, to the Fkh<sup>sf</sup> polypeptide.

21. (Amended) The method of any one of claims 20, 35-36 wherein said antibody is selected from the group consisting of:

- (a) polyclonal antibody,
- (b) a murine monoclonal antibody,
- (c) a humanized antibody derived from (b),
- (d) a human monoclonal antibody, and

22. (Amended) The method of any one of claims 20, 35-36, wherein said antibody fragment is selected from the group consisting of F(ab')<sub>2</sub>, F(ab)<sub>2</sub>, Fab', Fab, Fv, sFv, and minimal recognition unit.

23. (Amended) The method of any one of claims 20, 35-36, wherein said antibody or said antibody fragment further comprises a detectable label selected from the group consisting of radioisotope, fluorescent label, chemiluminescent label, enzyme label, bioluminescent label, and colloidal gold.

*BB could*

---

Please add new claims 35-36 to read as follows:

---

35. (New) A method for detecting the presence of an FKH<sup>sf</sup> polypeptide in a biological sample, comprising the steps of:

*BA*

(a) contacting the biological sample with an antibody, or an antibody fragment thereof, that specifically binds to an FKH<sup>sf</sup> polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:4, under conditions that allow binding of the antibody or antibody fragment to the FKH<sup>sf</sup> polypeptide, and

(b) detecting binding of the antibody, or antibody fragment thereof, to the FKH<sup>sf</sup> polypeptide.